Considerations for the design of vaccine efficacy trials during public health emergencies
暂无分享,去创建一个
Christl A. Donnelly | Martha Nason | M. Elizabeth Halloran | Ira M. Longini | Pierre-Stéphane Gsell | Ana Maria Henao-Restrepo | Victor De Gruttola | Ron Brookmeyer | Natalie E. Dean | Momodou Jasseh | Ximena Riveros | Conall Watson | R. Brookmeyer | M. Halloran | N. Dean | C. Donnelly | I. Longini | V. De Gruttola | Momodou Jasseh | A. Henao-Restrepo | X. Riveros | C. Watson | M. Nason | P. Gsell
[1] M E Halloran,et al. Using validation sets for outcomes and exposure to infection in vaccine field studies. , 2001, American journal of epidemiology.
[2] Lawrence O Gostin,et al. Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola , 2015, The Lancet.
[3] Murray K. Clayton,et al. BAYES DISCRETE SEQUENTIAL BOUNDARIES FOR CLINICAL TRIALS , 2001 .
[4] M. Parmar,et al. More multiarm randomised trials of superiority are needed , 2014, The Lancet.
[5] John-Arne Røttingen,et al. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola , 2015, BMJ : British Medical Journal.
[6] Ross E. G. Upshur,et al. Randomized controlled trials in the West African Ebola virus outbreak , 2016, Clinical trials.
[7] M. Hudgens,et al. Toward Causal Inference With Interference , 2008, Journal of the American Statistical Association.
[8] S. Pocock. Group sequential methods in the design and analysis of clinical trials , 1977 .
[9] Susan S Ellenberg,et al. Evaluating interventions for Ebola: The need for randomized trials , 2016, Clinical trials.
[10] S. Piantadosi. Clinical Trials : A Methodologic Perspective , 2005 .
[11] David L. DeMets,et al. Data Monitoring Committees in Clinical Trials: A Practical Perspective , 2002 .
[12] Tony Vangeneugden,et al. Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges , 2016, Clinical trials.
[13] Sebastian Funk,et al. Estimating the probability of demonstrating vaccine efficacy in the declining Ebola epidemic: a Bayesian modelling approach , 2015, BMJ Open.
[14] Richard J. Hayes,et al. Cluster randomised trials , 2009 .
[15] Jennifer C Nelson,et al. The test-negative design for estimating influenza vaccine effectiveness. , 2013, Vaccine.
[16] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial , 2015, The Lancet.
[17] Emily R. Busta,et al. Integrating Clinical Research into Epidemic Response: The Ebola Experience , 2017 .
[18] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[19] C. Grady,et al. Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research , 2016, Journal of Medical Ethics.
[20] P. Ravaud,et al. Preventing Bias in Cluster Randomised Trials , 2009, PLoS medicine.
[21] Robert Pinner,et al. Implementing an Ebola Vaccine Study - Sierra Leone. , 2016, MMWR supplements.
[22] Peter B Gilbert,et al. A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens , 2011, Statistical communications in infectious diseases.
[23] A R Hinman,et al. Field evaluation of vaccine efficacy. , 1985, Bulletin of the World Health Organization.
[24] R. J. Hayes,et al. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases , 2000, Statistical methods in medical research.
[25] Adam J. Kucharski,et al. Guiding Vaccine Efficacy Trial Design During Public Health Emergencies: An interactive web-based decision support tool , 2018 .
[26] Alessandro Vespignani,et al. Simulations for designing and interpreting intervention trials in infectious diseases , 2017, bioRxiv.
[27] Pierre-Stéphane Gsell,et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report , 2017, The Lancet. Infectious diseases.
[28] Claudio J. Struchiner,et al. Design and Analysis of Vaccine Studies , 2009 .
[29] P A Lachenbruch,et al. Intent-to-treat analysis and preventive vaccine efficacy. , 2000, Vaccine.
[30] C. Bias. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials , 2011 .
[31] P. O'Brien,et al. A multiple testing procedure for clinical trials. , 1979, Biometrics.
[32] De Phung. Clinical trials: a methodologic perspective (second edition) Piantadosi S (2005)ISBN: 0471727814; 687 pages; £64.95; ??91.70; $110.00 Wiley; , 2006 .
[33] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.
[34] M Elizabeth Halloran,et al. DESIGN OF VACCINE TRIALS DURING OUTBREAKS WITH AND WITHOUT A DELAYED VACCINATION COMPARATOR. , 2018, The annals of applied statistics.
[35] David L. DeMets,et al. Data Monitoring Committees in Clinical Trials , 2002 .
[36] Martha Nason,et al. Statistics and logistics: Design of Ebola vaccine trials in West Africa , 2016, Clinical trials.
[37] Kai Kupferschmidt,et al. Infectious Diseases. Ebola vaccine trials raise ethical issues. , 2014, Science.
[38] Lauren Ancel Meyers,et al. Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. , 2015, The Lancet. Infectious diseases.
[39] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[40] M E Halloran,et al. Measuring vaccine efficacy from epidemics of acute infectious agents. , 1993, Statistics in medicine.
[41] Marie Paule Kieny,et al. WHO R&D Blueprint: a global coordination mechanism for R&D preparedness , 2017, The Lancet.
[42] Domenic J. Reda,et al. Clinical Trials Design in Operative and Non Operative Invasive Procedures , 2017 .
[43] Thomas R Fleming,et al. Current issues in non‐inferiority trials , 2008, Statistics in medicine.